This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Tianyin Pharmaceutical CEO Discusses F2Q2011 Results - Earnings Call Transcript

Tianyin Pharmaceutical Co. Inc. ( TPI)

F2Q2011 Earnings Call

February 15, 2011 9:00 AM ET

Executives

James Jiayuan Tong – CFO, Chief Business & Development Officer

Jiang Guoqing – Chairman and CEO

Analysts

Adam Waldo [ph] – Lismore Partners [ph]

Mark McLachlan [ph] – Mainstream Investment Advisers

Angel Liu – Pope Asset Management

Saul Rosenthal [ph] – Private Investor

Boyd Hinds – Equinox Capital

Presentation

Operator

Good morning, ladies and gentlemen, and thank you for standing by. Welcome to the Tianyin Pharmaceutical Incorporated Second Quarter Earnings Conference Call. (Operator Instructions).

And at this time, I would now like to turn the conference over to Dr. James Tong, who’s Chief Financial Officer and Chief Business Development Officer. Please go ahead.

James Jiayuan Tong

Thank you, operator. Good morning. Good evening. Ladies and gentlemen, welcome to Tianyin Pharmaceutical TPI Second Quarter Fiscal Year 2011 Earnings Conference Call. I am James Jiayuan Tong, Chief Financial Officer and Chief Business and Development Officer at TPI along with Dr. Jiang Guoqing, Chief Executive Officer and Chairman of the company; and Simon Min Ren, Director of Investor Relations; and May Yenyuhan [ph], Assistant to CFO.

During this conference call, we will be reviewing the second quarter fiscal year 2011 financial highlights followed by the question and answer period. Before we continue, please not that this call will contain forward-looking statements made under the Safe Harbor provisions of the US Private Security Litigation Reform Act of 1995.

Any statements set forth in this presentation, that are not historical facts or forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include but are not limited to such factors as unanticipated changes in the product demand, increased competition, failure to obtain or maintain intellectual property protection, fluctuation in the economy, results of research and development, failure to obtain regulatory approvals and other information detailed from time to time in TPI’s filing and future filings with the United States Securities and Exchange Commission.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,088.02 +50.05 0.28%
S&P 500 2,111.76 +2.84 0.13%
NASDAQ 5,056.3740 -3.8720 -0.08%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs